Columbia, MD—April 16, 2026—Precision Antibody, a leader in custom monoclonal antibody development, is proud to announce its participation and scientific presentations at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California.

Hosted by the American Association for Cancer Research, the AACR Annual Meeting is one of the world’s most prestigious cancer research conferences, bringing together leading scientists, clinicians, and industry experts to showcase cutting-edge advances in oncology and translational medicine.

At this year’s meeting, Precision Antibody will present two poster presentations highlighting its advancements in fully human monoclonal antibody development for oncology applications, including antibody-drug conjugates (ADCs). Notably, these fully human antibodies were developed in approximately 60 days, demonstrating the company’s ability to accelerate discovery timelines without compromising quality.

Poster Presentation Details
Poster #1: Fully human monoclonal antibodies for ADC development to a cell surface target expressed in cancers with unmet needs
Date: April 19, 2026
Time: 2:00 – 5:00 PM
Abstract # 3613
Poster Section: 18
Board # 30

Poster #2: Title: Fully human anti-HER-2 antibodies with distinct epitopes as superior ADCs for tumor growth inhibition
Date: April 20, 2026
Time: 2:00 – 5:00 PM
Abstract # 3168
Poster Section: 19
Board # 3

These presentations underscore Precision Antibody’s expertise in generating high-affinity, epitope-rich, and fully functional monoclonal antibodies designed to support next-generation cancer therapeutics and ADC development.

“We are excited to present our latest research at AACR 2026 and contribute to the advancement of oncology therapeutics,” said Dr. Serrero. “Our ability to develop fully human monoclonal antibodies in as little as 60 days is helping accelerate drug discovery and enabling our partners to move faster toward clinical success.”

As biomarker antibody specialists, Precision Antibody has a strong track record of developing high-quality biomarker antibodies for oncology research. The company is also a proud contributor to the National Cancer Institute’s Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies widely used in cancer biomarker research.

Precision Antibody invites attendees of the AACR Annual Meeting 2026 to visit their poster sessions and connect with the team to learn more about their rapid, royalty-free fully human monoclonal antibody development platform.

About Precision Antibody
Founded in 2000, Precision Antibody is a U.S.-based biotechnology company specializing in the rapid development of custom monoclonal antibodies. Known for delivering antibodies that work “right the first time,” the company supports pharmaceutical, biotech, academic, and government researchers worldwide. With a proven track record in biomarker antibody development and contributions to the NCI’s Clinical Proteomic Technologies for Cancer (CPTC) program, Precision Antibody is recognized for setting benchmarks in antibody quality and reliability. In 2025, the company was honored as the Best Monoclonal Antibody Development Company, reinforcing its leadership and commitment to advancing diagnostics, therapeutics, and translational research through high-performance, royalty-free antibodies.

Media Contact:
Precision Antibody
Dr. Jun Hayashi
President
Phone: 410-884-4100
Email: [email protected]
Website: www.precisionantibody.com

Event Details:
AACR Annual Meeting 2026
Dates: April 17–22, 2026
Location: San Diego, California, USA
Event Website: https://www.aacr.org/meeting/aacr-annual-meeting-2026/